[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369062-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369062-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","urinary-tumor-dna-to-identify-candidates-for-repeat-transurethral-resection-in-non-muscle-invasive-bladder-cancer","Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non-Muscle-Invasive Bladder Cancer","","Repeat transurethral resection of bladder tumor (re-TURBT) is recommended for non–muscle-invasive bladder cancer (NMIBC) patients with high-risk features, yet many undergo avoidable procedures that raise morbidity without clear benefit. Urinary tumor DNA (utDNA) is evaluated as a biomarker. In a retrospective cohort of 161 patients receiving re-TURBT (May 2020–May 2025), urine collected 2–6 weeks after initial TURBT was analyzed by a multidimensional utDNA assay (utLIFE). Residual tumor was found in 35%, with sensitivity 80.7%, specificity 96.2%, and accuracy 90.7%, outperforming urine cytology. A positive utLIFE strongly predicted residual disease (OR 77.5; p\u003C0.001) and shorter recurrence-free survival (HR 16.4; p=0.003).",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/urinary-tumor-dna-to-identify-candidates-for-repeat-transurethral-resection-in-non-muscle-invasive-bladder-cancer/369062/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/urinary-tumor-dna-to-identify-candidates-for-repeat-transurethral-resection-in-non-muscle-invasive-bladder-cancer/369062.png","ImageObject",300,407,{"name":42,"@type":43},"pixelkiddo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-09","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical problem does the study address?","Question",{"text":63,"@type":64},"It addresses overtreatment in high-risk NMIBC patients by evaluating whether urinary tumor DNA can better identify who truly has residual disease after initial TURBT before re-TURBT.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was urinary tumor DNA measured in this study?",{"text":68,"@type":64},"Urine samples collected 2–6 weeks after initial TURBT were analyzed using utLIFE, which combines shallow whole-genome sequencing with targeted sequencing of 155 genes and machine learning–based classification.",{"name":70,"@type":61,"acceptedAnswer":71},"How accurate was utLIFE compared with urine cytology?",{"text":72,"@type":64},"utLIFE showed high diagnostic accuracy with sensitivity 80.7%, specificity 96.2%, and overall accuracy 90.7%, markedly outperforming urine cytology.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369062,1790199646,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","Cancer Science  \nORIGINAL ARTICLE  OPEN ACCESS   \nUrinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non-Muscle-Invasive Bladder Cancer  \nZihan Xue1,2  | Yunkai Qie1,2 | Chong Shen1,2 | Zhouliang Wu1,2  | Houyuan Chen1,2 | Yuda Lin1,2 | Rongjiang Li1,2 | Shiwang Huang1,2 | Hailong Hu1,2   \n1Department of Urology, Second Hospital of Tianjin Medical University, Tianjin, China | 2Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Tianjin, China  \nCorrespondence: Yunkai Qie ([qieyunkai@tmu.edu.cn](qieyunkai@tmu.edu.cn)) | Hailong Hu ([huhailong@tmu.edu.cn](huhailong@tmu.edu.cn))  \nReceived: 8 September 2025 | Revised: 11 December 2025 | Accepted: 17 December 2025  \nKeywords: bladder cancer | liquid biopsy | precision oncology | transurethral resection of bladder tumor | urinary tumor DNA  \nABSTRACT  \nRepeat transurethral resection of bladder tumor (re-TURBT) is commonly recommended for patients with non–muscle-invasive bladder cancer (NMIBC) with high-risk features, although many individuals may undergo unnecessary procedures that increase morbidity without clear benefit. Urinary tumor DNA (utDNA) has emerged as a promising biomarker, and we evaluated the performance of a multidimensional utDNA assay (utLIFE) in this context. In a retrospective cohort of 161 patients who underwent re-TURBT between May 2020 and May 2025, urine samples collected 2–6 weeks after initial TURBT were analyzed using utLIFE, which integrates shallow whole-genome sequencing and targeted sequencing of 155 genes with machine learning–based classification. Residual tumor was identified in 35% of patients, and utLIFE demonstrated high diagnostic accuracy, with sensitivity of 80.7%, specificity of 96.2%, and overall accuracy of 90.7%, markedly outperforming urine cytology. A positive utLIFE result was the strongest independent predictor of residual disease (OR = 77.5, 95% CI: 22.4–268.2, p \u003C 0.001) . During a median follow-up of 32.5 months, recurrence occurred in 20.5% of patients; recurrence was defined as urothelial tumor relapse within the urinary tract and did not include distant metastasis. utLIFE positivity was significantly associated with shorter recurrencefree survival (HR = 16.4, 95% CI: 2.7–101.8, p = 0.003) . Longitudinal testing further revealed that utDNA positivity frequently preceded cystoscopic evidence of recurrence by several months. These findings highlight the strong diagnostic and prognostic value of utDNA in identifying residual disease and predicting recurrence, supporting its potential role in refining postoperative management strategies for NMIBC.  \n1 | Introduction  \nBladder cancer (BC) ranks among the most prevalent malignancies worldwide [1], with approximately 75% of cases classified as non-muscle-invasive bladder cancer (NMIBC) [2] .  \nAlthough favorable survival, NMIBC is characterized by frequent recurrences, requiring close surveillance and repeated interventions. To improve staging accuracy and ensure complete resection, international guidelines recommend repeat transurethral resection (re-TURBT) in patients with high-risk  \n\n| Abbreviations: BC, bladder cancer; CI, confidence interval; CIS, carcinoma in situ; CNV, copy number variation; ctDNA, circulating tumor DNA; DCA, decision curve analysis; DM, detrusor muscle; EAU, European Association of Urology; HG, high grade; HR, hazard ratio; IQR, interquartile range; LG, low grade; NMIBC, non–muscle-invasive bladder cancer; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive value; RFS, recurrence-free survival; SPSS, Statistical Package for the Social Sciences; UC, urothelial carcinoma; ucfDNA, urine cell-free DNA; uexDNA, urine-exfoliated cell DNA; utDNA, urinary tumor DNA; utLIFE, urinary tumor DNA–based multidimensional model; WGS, whole-genome sequencing. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial Lice","cbCaiuVWU8B4u8r5","https://ap.wps.com/l/cbCaiuVWU8B4u8r5","pdf",1306279,"English","# Introduction\n# Material and Methods\n## Study Design","[{\"question\":\"What clinical problem does the study address?\",\"answer\":\"It addresses overtreatment in high-risk NMIBC patients by evaluating whether urinary tumor DNA can better identify who truly has residual disease after initial TURBT before re-TURBT.\"},{\"question\":\"How was urinary tumor DNA measured in this study?\",\"answer\":\"Urine samples collected 2–6 weeks after initial TURBT were analyzed using utLIFE, which combines shallow whole-genome sequencing with targeted sequencing of 155 genes and machine learning–based classification.\"},{\"question\":\"How accurate was utLIFE compared with urine cytology?\",\"answer\":\"utLIFE showed high diagnostic accuracy with sensitivity 80.7%, specificity 96.2%, and overall accuracy 90.7%, markedly outperforming urine cytology.\"}]","Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non-Muscle-Invasive Bladder Cancer | PDF",1790180455,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d49c06e5bd3dc4f823634f670ede2cf.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/104400b87f05e9ef672b4ff210e4af34.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d84e8a29c789673e98d6244d415a5de9.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61e50e2e8152254d60ce957fc8ba109d.webp",980,1287]